Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"

COVID-19 Clinical Trial

Official title:

Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: "The Hope Coalition"

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04403100
• Other study ID #: COVID19_AMB_Brasil
• Status: Recruiting
• Phase: Phase 3
• Start date: June 3, 2020
• Est. completion date: February 1, 2021

Study information

• Verified date: January 2021
• Source: Cardresearch
• Contact: Gilmar Reis, MD, PhD
• Phone: +5531332416574
• Email: greisbh[@]uol.com.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients with moderate and / or severe cases of this disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV viral replication in experimental severe acute respiratory symptoms models and have similar activity against SARS-CoV2. Although widely used in studies of critically ill patients, to date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed patients with COVID-19 and mild symptoms.

Description:

In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China. A new subtype of coronavirus has been identified as the causative agent of this condition. On February 11, 43,103 cases had already been described and on this day the World Health Organization (WHO) named this disease as COVID-19. With. The disease had spread out to several countries on different continents and on March 11, WHO declared a state of worldwide pandemic. Today (April 25, 2020) there are 2,719,897 cases and 187,705 deaths documented, with a global case-fatality ratio of 6.9%.

To date, no treatment has been identified as effective in combating this disease which has been identified as with high mortality, therefore there are no specific therapeutic options. So far, efforts have been focused on the treatment of patients hospitalized with dyspnea and, although several promising drugs are being evaluated, none has demonstrated effectiveness in reducing morbidity and mortality at this stage of the disease, suggesting that perhaps the best time to use medications either before the onset of severe symptoms of respiratory distress.

Thus, we propose the use of two drugs which experimentally have shown activity against SARS-CoV2 and being used in severely ill patients with COVID-19. Our hypothesis is that perhaps using such drugs before onset of complications will allow better outcomes on this patient population.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1968
• Est. completion date: February 1, 2021
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients with RT-PCR diagnosis of COVID-19 or a clinical condition compatible with COVID-19 and respiratory symptoms, presenting:

A. Persistent dry cough associated with axillary temperature > 37.7 Celsius;

OR

B. Recent onset of Flu-like Respiratory Symptoms associated with dry cough

OR

C. Tomographic image compatible with COVID 19 infection;

2. Men and women aged > 50 years OR: Patients over 18 years of age with at least one of the following criteria

• Diabetes requiring oral medication or insulin.

• Arterial hypertension requiring at least 01 oral medication for treatment

• Known cardiovascular diseases (CHF of any etiology, documented Coronary Artery Disease, Clinically overt heart disease)

• Symptomatic chronic lung disease and/ or medically controlled

• Patients with a history of transplantation

• Patient with stage IV chronic kidney disease or on dialysis.

• Patients on current Immunosuppression and/or using corticosteroid therapy (equivalent to at least 10 mg of oral prednisone per day)

• Willingness to comply with study related procedures

3. Ability to provide informed consent before any protocol-related procedures.

Exclusion Criteria:

1. RT-PCR exam for COVID-19 negative during the screening visit.

2. Patients with an acute respiratory condition compatible with COVID-19 being hospitalized;

3. Patients with an acute respiratory condition and with moderate to high probability of not being a COVID infection 19;

4. Dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated Chronic Obstructive Pulmonary Disease, acute bronchitis, pneumonia, primary pulmonary arterial hypertension);

5. Severe respiratory clinical condition, presenting at least ONE of the criteria below:

1. Respiratory Rate> 28 / min;

2. Arterial Oxygen Saturation < 92% with nasal oxygen therapy at 10 l/ min;

3. PaO2 / FIO2 <300 mmHg

4. History of Cardiac Arrhythmia or Long QT Syndrome; 5. Use of Medications that are known to prolong QTc: Citalopram, Venlafaxine, Bupropion and with no possibility of suspension during the period of investigational medical product administration. 6. Inability to take oral medications; 7. Patients on continuous use of Amiodarone and / or PGE5 Inhibitors (Ex .: Sildenafil and similar). 8. Use of Digoxin, Cyclosporine, Cimetidine, Tamoxifen. 9. Use of anticonvulsants, antifungals, immunosuppressants other than corticotherapy. 10. Use of Hydroxychloroquine for other indications 11. Use of chemoprophylaxis for malaria. 12. Psoriasis in a form other than cutaneous 13. Porphyria 14. Use of protease inhibitors, ritonavir or Cobicistat 15. Clinical history of Liver Cirrhosis or Child-Pugh C classification; 16. Patients with a history of degenerative retinal diseases (patients with retinal diseases due to diabetes and hypertension can participate in the research); 17. Patient with a clinically relevant history of hearing loss; 18. Patients with known severe degenerative neurological diseases and / or severe mental illness; 19. Inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. Known hypersensitivity and / or intolerance to Hydroxychloroquine. 21. Hypersensitivity and / or intolerance Lopinavir / Ritonavir

-

Related Conditions & MeSH terms

• Acute Respiratory Infection
• Communicable Diseases
• Coronavirus Infection
• Coronavirus Infections
• COVID-19
• Infection
• Respiratory Tract Infections
• SARS-CoV Infection
• Severe Acute Respiratory Syndrome
• Virus Disease
• Virus Diseases

Intervention

Drug:
• Hydroxychloroquine Sulfate Tablets
Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
• Lopinavir/ Ritonavir Oral Tablet
tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
• Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets
Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days plus Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
• Placebo
Placebo tablets - 01 tablet twice daily from day 01 through day 10.

Locations

Country	Name	City	State
Brazil	CARDRESEARCH - Cardiologia Assistencial e de Pesquisa	Belo Horizonte	Minas Gerais
Brazil	Pontificia Universidade Catolica de Minas Gerais	Belo Horizonte	Minas Gerais
Brazil	Fundo Municipal de Saúde de Betim	Betim	Minas Gerais
Brazil	Universidade Federal de Ouro Preto	Ouro Preto	Minas Gerais

Sponsors (3)

Lead Sponsor	Collaborator
Cardresearch	Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA, Cytel Inc.

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants who were hospitalized for progression of COVID-19 disease	Hospitalization is defined as at least 24 hours of acute care in a hospital or similar acute care facility (emergency settings, temporary emergency facilities created for acute care of COVID-19 pandemic)	Measuring during 28-day period since randomization (Intention to treat analysis)
Primary	Proportion of participants who died due to COVID-19 progression and/ or complications		Measuring during 28-day period since randomization (Intention to treat analysis)
Secondary	Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization	Viral load change on 03, 07, 10 and 14 after randomization (200 patients per arm)	Measuring during 14-day period since randomization
Secondary	Time to clinical improvement	Proportion of participants with clinical improvement, defined as normalization of temperature, Respiratory rate, SaO2, and cough relief (> 50% compared to baseline measured on a visual analog scale) in the last 72 hours.	Measuring during 28-day period since randomization
Secondary	Time to clinical failure	Proportion of participants with clinical improvement, defined as as time to need for hospitalization due to dyspnea, death, need for mechanical ventilation, shock and need for vasoactive amines;	Measuring during 28-day period since randomization
Secondary	Hospitalization for any cause	Proportion of participants with hospitalization for any cause	Measuring during 28-day period since randomization
Secondary	Proportion of participants who died due to pulmonary complications		Measuring during 28-day period since randomization
Secondary	Proportion of participants who died due to cardiovascular complications		Measuring during 28-day period since randomization
Secondary	Proportion of participants who presented with adverse events	Evaluation of adverse events evaluated as associated to any of study arms	Measuring during 28-day period since randomization
Secondary	Time to improvement on respiratory scale symptoms	Proportion of participants who presented sustained improvement on respiratory scale defined as at least 48 hours of improvement.	Measuring during 28-day period since randomization
Secondary	proportion of non-adherent participants to any of study drugs		Measuring during 10-day period since randomization